Kolexia
Levy Christelle Oncologie médicale
Levy Christelle
Oncologie médicale
Centre François-Baclesse
Caen, France
305 Activités
7 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Récidive tumorale locale Tumeurs du sein triple-négatives Tumeur du sein de l'homme Fatigue Cancers du sein inflammatoires Tumeurs du cerveau Métastase lymphatique

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France

Industries

Voir plus
Lilly
15 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023
Gilead
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
APHINITY: A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Essai Clinique (Roche)   21 décembre 2023
DAISY: Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy
Essai Clinique (Daiichi Sankyo)   06 décembre 2023
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
SOLAR-1: A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Essai Clinique (Novartis)   17 novembre 2023
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
JAMA network open   01 novembre 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA oncology   19 octobre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023